Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
News|Articles|September 30, 2026
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
Author(s)Leah Kuntz
Check out our pipeline updates from September!
Advertisement
Advertisement
Take a look at this month’s developments in the psychiatric treatment pipeline. We compiled a recap of the latest news here, just in case you missed any of the updates.
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
Advertisement
Advertisement